DAVID GILL

Currently, Mr. Gill serves on the boards of two public companies: Y-mAbs Therapeutics (YMAB), an immuno-oncology company focused on pediatric brain cancer, and Evolus (EOLS), an aesthetics company. In addition, he serves on the boards of several private companies including as the Chairman of Healthtronics, Inc, a mobile surgical equipment company, as well as AlphaSource, a leading provider of imaging equipment parts and service. Mr. Gill’s other private company boards include RapidPulse, Inc., an ischemic stroke medical device company, Bridge to Life Ltd, a leading company in the organ transplantation market and Perimetrics AI, a dental diagnostic company. 

In his most recent operating role Mr. Gill joined Endochoice (NYSE: GI) in August 2014 as CFO, executed its IPO in June 2015, and then later assumed the added roles of President and Chief Operating Officer in March 2016. EndoChoice was a 500-employee public medical device company with operations in US, Germany and Israel. Boston Scientific acquired Endochoice in November 2016, at which point Mr. Gill retired.  Prior to Endochoice he was the CFO of INC Research, now known as Syneos Health.

Earlier in his career Mr. Gill served in a variety of senior leadership roles (president, COO and CFO) for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Novoste Corporation and Dornier Medical.

Mr. Gill has led the IPO’s of four companies and has raised more than $1.3 Billion in equity and debt during his career. He graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned an MBA (with distinction) from Emory University.